DCIS patients receiving anastrozole reported symptoms different from those receiving
Both groups reported similar quality of life. Analysis of patient-reported outcomes (PRO), a secondary endpoint of the phase III, NSABP B-35 clinical trial, in which anastrazole and tamoxifen were...